Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
LIVONIA, Mich., Oct. 26, 2016 -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia and NAFLD/NASH (nonalcoholic fatty liver disease), today announced that it will issue a press release announcing financial results for the third quarter ended September 30, 2016 on Wednesday, November 2.
The Company also announced that Mina Sooch, Gemphire’s CEO, will be presenting at the 25th Annual Credit Suisse 2016 Healthcare Conference, being held at the Phoenician Hotel in Scottsdale, Arizona, November 7-8.
| 25th Annual Credit Suisse Healthcare Conference Presentation Details: | |
| Date: | Monday, November 7 |
| Time: | 10:00am Mountain Time/12:00pm Eastern Time |
| Location: | Phoenician Hotel, Ballroom G |
The presentation slides will be available immediately prior to and for 90 days following the presentation on the Investors and Media page of Gemphire’s website at http://ir.gemphire.com.
About Gemphire
Gemphire is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease, and NAFLD/NASH (nonalcoholic fatty liver disease). Please visit www.gemphire.com for more information.
Contact: Andrew McDonald, Ph.D. LifeSci Advisors, LLC (646) 597-6987 Jeff Mathiesen, CFO Gemphire Therapeutics (734)-245-1700
